- Home
- CRVS vs QUAD Comparison
CRVS vs QUAD Comparison
Compare CRVS & QUAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- QUAD
- Stock Information
- Founded
- CRVS 2014
- QUAD 1971
- Country
- CRVS United States
- QUAD United States
- Employees
- CRVS N/A
- QUAD N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- QUAD Publishing
- Sector
- CRVS Health Care
- QUAD Consumer Discretionary
- Exchange
- CRVS Nasdaq
- QUAD Nasdaq
- Market Cap
- CRVS 335.1M
- QUAD 408.6M
- IPO Year
- CRVS 2016
- QUAD 2010
- Fundamental
- Price
- CRVS $4.88
- QUAD $7.62
- Analyst Decision
- CRVS Strong Buy
- QUAD Strong Buy
- Analyst Count
- CRVS 5
- QUAD 2
- Target Price
- CRVS $12.38
- QUAD $10.15
- AVG Volume (30 Days)
- CRVS 393.6K
- QUAD 222.2K
- Earning Date
- CRVS 03-18-2025
- QUAD 02-18-2025
- Dividend Yield
- CRVS N/A
- QUAD 2.96%
- EPS Growth
- CRVS N/A
- QUAD N/A
- EPS
- CRVS N/A
- QUAD N/A
- Revenue
- CRVS N/A
- QUAD $2,751,700,000.00
- Revenue This Year
- CRVS N/A
- QUAD N/A
- Revenue Next Year
- CRVS N/A
- QUAD N/A
- P/E Ratio
- CRVS N/A
- QUAD N/A
- Revenue Growth
- CRVS N/A
- QUAD N/A
- 52 Week Low
- CRVS $1.30
- QUAD $4.06
- 52 Week High
- CRVS $10.00
- QUAD $9.13
- Technical
- Relative Strength Index (RSI)
- CRVS 39.47
- QUAD 59.39
- Support Level
- CRVS $5.02
- QUAD $6.57
- Resistance Level
- CRVS $5.19
- QUAD $6.93
- Average True Range (ATR)
- CRVS 0.32
- QUAD 0.42
- MACD
- CRVS 0.02
- QUAD 0.09
- Stochastic Oscillator
- CRVS 26.67
- QUAD 79.19
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market.